ATENOLOL
All products: general benefit
Other products in the same Health Canada class (C07A, C07AB) — coverage varies; not interchangeable
- Acebutolol (Sectral): general benefit, Not a benefit
- Bisoprolol (Sandoz Bisoprolol Tablets): general benefit, Not a benefit
- Metoprolol (Lopresor SR): general benefit, Not a benefit
- Nebivolol (Bystolic): not a benefit
- Labetalol (Trandate): general benefit
- Nadolol (Corgard): general benefit, Not a benefit
5 more in the class list below
Apo-Atenol · DIN 00773689 · 50mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Atenol · DIN 00773689
Manufacturer: Apotex Inc.; listing date 1996-10-01
Daily cost (source): $0.0938
Health Canada: Marketed since 1988-12-31 · brand APO-ATENOL TAB 50MG · ATC C07AB03 ATENOLOL · form Tablet · route Oral · ingredients ATENOLOL 50 MG · company Apotex inc · schedule Prescription
Apo-Atenol: Formulary list price $0.0938/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0938 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9174 · Verify on the e-Formulary ↗ (DIN 00773689)
Source record
DIN 00773689: Apo-Atenol
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400079; group id 276; item number 0570; lccId None; manufacturer id APX
Source form: Tab; strength: 50mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0938; ministry $0.0938
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00773689
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9174
Interchangeable products
AG-Atenolol · DIN 02369184 · $0.0938
Atenolol · DIN 02238316 · $0.0938
Atenolol · DIN 02466465 · $0.0938
Jamp-Atenolol · DIN 02367564 · $0.0938
Mar-Atenolol · DIN 02371987 · $0.0938
Mint-Atenol · DIN 02368021 · $0.0938
PMS-Atenolol · DIN 02237600 · $0.0938
Ran-Atenolol · DIN 02267985 · $0.0938
Ratio-Atenolol · DIN 02171791 · $0.0938
Septa-Atenolol · DIN 02368641 · $0.0938
Tenormin · DIN 02039532 · $0.0938
Teva-Atenolol · DIN 01912062 · $0.0938
Shortage status: active shortage (reported 2025-10-14, last updated 2025-10-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00773689
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Atenolol · DIN 02238316 · 50mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Atenolol · DIN 02238316
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2010-06-14
Daily cost (source): $0.0938
Health Canada: Marketed since 2024-01-05 · brand ATENOLOL · ATC C07AB03 ATENOLOL · form Tablet · route Oral · ingredients ATENOLOL 50 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Atenolol: Formulary list price $0.0938/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0938 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61718 · Verify on the e-Formulary ↗ (DIN 02238316)
Source record
DIN 02238316: Atenolol
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400079; group id 276; item number 0570; lccId None; manufacturer id SIV
Source form: Tab; strength: 50mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0938; ministry $0.0938
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02238316
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61718
Interchangeable products
AG-Atenolol · DIN 02369184 · $0.0938
Apo-Atenol · DIN 00773689 · $0.0938
Atenolol · DIN 02466465 · $0.0938
Jamp-Atenolol · DIN 02367564 · $0.0938
Mar-Atenolol · DIN 02371987 · $0.0938
Mint-Atenol · DIN 02368021 · $0.0938
PMS-Atenolol · DIN 02237600 · $0.0938
Ran-Atenolol · DIN 02267985 · $0.0938
Ratio-Atenolol · DIN 02171791 · $0.0938
Septa-Atenolol · DIN 02368641 · $0.0938
Tenormin · DIN 02039532 · $0.0938
Teva-Atenolol · DIN 01912062 · $0.0938
Shortage status: resolved shortage (ended 2024-12-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02238316
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp-Atenolol · DIN 02367564 · 50mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp-Atenolol · DIN 02367564
Manufacturer: Jamp Pharma Corporation; listing date 2012-01-19
Daily cost (source): $0.0938
Health Canada: Marketed since 2011-06-09 · brand JAMP-ATENOLOL · ATC C07AB03 ATENOLOL · form Tablet · route Oral · ingredients ATENOLOL 50 MG · company Jamp pharma corporation · schedule Prescription
Jamp-Atenolol: Formulary list price $0.0938/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0938 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85240 · Verify on the e-Formulary ↗ (DIN 02367564)
Source record
DIN 02367564: Jamp-Atenolol
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400079; group id 276; item number 0570; lccId None; manufacturer id JPC
Source form: Tab; strength: 50mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0938; ministry $0.0938
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02367564
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85240
Interchangeable products
AG-Atenolol · DIN 02369184 · $0.0938
Apo-Atenol · DIN 00773689 · $0.0938
Atenolol · DIN 02238316 · $0.0938
Atenolol · DIN 02466465 · $0.0938
Mar-Atenolol · DIN 02371987 · $0.0938
Mint-Atenol · DIN 02368021 · $0.0938
PMS-Atenolol · DIN 02237600 · $0.0938
Ran-Atenolol · DIN 02267985 · $0.0938
Ratio-Atenolol · DIN 02171791 · $0.0938
Septa-Atenolol · DIN 02368641 · $0.0938
Tenormin · DIN 02039532 · $0.0938
Teva-Atenolol · DIN 01912062 · $0.0938
Shortage status: resolved shortage (ended 2026-03-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02367564
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mar-Atenolol · DIN 02371987 · 50mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mar-Atenolol · DIN 02371987
Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2012-01-19
Daily cost (source): $0.0938
Health Canada: Marketed since 2012-10-22 · brand MAR-ATENOLOL · ATC C07AB03 ATENOLOL · form Tablet · route Oral · ingredients ATENOLOL 50 MG · company Marcan pharmaceuticals inc · schedule Prescription
Mar-Atenolol: Formulary list price $0.0938/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0938 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85711 · Verify on the e-Formulary ↗ (DIN 02371987)
Source record
DIN 02371987: Mar-Atenolol
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400079; group id 276; item number 0570; lccId None; manufacturer id MAR
Source form: Tab; strength: 50mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0938; ministry $0.0938
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02371987
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85711
Interchangeable products
AG-Atenolol · DIN 02369184 · $0.0938
Apo-Atenol · DIN 00773689 · $0.0938
Atenolol · DIN 02238316 · $0.0938
Atenolol · DIN 02466465 · $0.0938
Jamp-Atenolol · DIN 02367564 · $0.0938
Mint-Atenol · DIN 02368021 · $0.0938
PMS-Atenolol · DIN 02237600 · $0.0938
Ran-Atenolol · DIN 02267985 · $0.0938
Ratio-Atenolol · DIN 02171791 · $0.0938
Septa-Atenolol · DIN 02368641 · $0.0938
Tenormin · DIN 02039532 · $0.0938
Teva-Atenolol · DIN 01912062 · $0.0938
Shortage status: resolved shortage (ended 2018-09-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02371987
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mint-Atenol · DIN 02368021 · 50mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mint-Atenol · DIN 02368021
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2012-01-19
Daily cost (source): $0.0938
Health Canada: Marketed since 2011-06-13 · brand MINT-ATENOL · ATC C07AB03 ATENOLOL · form Tablet · route Oral · ingredients ATENOLOL 50 MG · company Mint pharmaceuticals inc · schedule Prescription
Mint-Atenol: Formulary list price $0.0938/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0938 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85284 · Verify on the e-Formulary ↗ (DIN 02368021)
Source record
DIN 02368021: Mint-Atenol
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400079; group id 276; item number 0570; lccId None; manufacturer id MIN
Source form: Tab; strength: 50mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0938; ministry $0.0938
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02368021
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85284
Interchangeable products
AG-Atenolol · DIN 02369184 · $0.0938
Apo-Atenol · DIN 00773689 · $0.0938
Atenolol · DIN 02238316 · $0.0938
Atenolol · DIN 02466465 · $0.0938
Jamp-Atenolol · DIN 02367564 · $0.0938
Mar-Atenolol · DIN 02371987 · $0.0938
PMS-Atenolol · DIN 02237600 · $0.0938
Ran-Atenolol · DIN 02267985 · $0.0938
Ratio-Atenolol · DIN 02171791 · $0.0938
Septa-Atenolol · DIN 02368641 · $0.0938
Tenormin · DIN 02039532 · $0.0938
Teva-Atenolol · DIN 01912062 · $0.0938
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02368021
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Atenolol · DIN 02237600 · 50mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PMS-Atenolol · DIN 02237600
Manufacturer: Pharmascience Inc.; listing date 1999-04-15
Daily cost (source): $0.0938
Health Canada: Marketed since 1998-03-31 · brand PMS-ATENOLOL · ATC C07AB03 ATENOLOL · form Tablet · route Oral · ingredients ATENOLOL 50 MG · company Pharmascience inc · schedule Prescription
PMS-Atenolol: Formulary list price $0.0938/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0938 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60939 · Verify on the e-Formulary ↗ (DIN 02237600)
Source record
DIN 02237600: PMS-Atenolol
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400079; group id 276; item number 0570; lccId None; manufacturer id PMS
Source form: Tab; strength: 50mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0938; ministry $0.0938
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02237600
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60939
Interchangeable products
AG-Atenolol · DIN 02369184 · $0.0938
Apo-Atenol · DIN 00773689 · $0.0938
Atenolol · DIN 02238316 · $0.0938
Atenolol · DIN 02466465 · $0.0938
Jamp-Atenolol · DIN 02367564 · $0.0938
Mar-Atenolol · DIN 02371987 · $0.0938
Mint-Atenol · DIN 02368021 · $0.0938
Ran-Atenolol · DIN 02267985 · $0.0938
Ratio-Atenolol · DIN 02171791 · $0.0938
Septa-Atenolol · DIN 02368641 · $0.0938
Tenormin · DIN 02039532 · $0.0938
Teva-Atenolol · DIN 01912062 · $0.0938
Shortage status: discontinued (2023-09-08, reported by PHARMASCIENCE INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02237600
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Ran-Atenolol · DIN 02267985 · 50mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Ran-Atenolol · DIN 02267985
Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2006-03-01
Daily cost (source): $0.0938
Health Canada: Marketed since 2020-01-23 · brand TARO-ATENOLOL · ATC C07AB03 ATENOLOL · form Tablet · route Oral · ingredients ATENOLOL 50 MG · company Sun pharma canada inc · schedule Prescription
Ran-Atenolol: Formulary list price $0.0938/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0938 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75337 · Verify on the e-Formulary ↗ (DIN 02267985)
Source record
DIN 02267985: Ran-Atenolol
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400079; group id 276; item number 0570; lccId None; manufacturer id RAN
Source form: Tab; strength: 50mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0938; ministry $0.0938
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02267985
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75337
Interchangeable products
AG-Atenolol · DIN 02369184 · $0.0938
Apo-Atenol · DIN 00773689 · $0.0938
Atenolol · DIN 02238316 · $0.0938
Atenolol · DIN 02466465 · $0.0938
Jamp-Atenolol · DIN 02367564 · $0.0938
Mar-Atenolol · DIN 02371987 · $0.0938
Mint-Atenol · DIN 02368021 · $0.0938
PMS-Atenolol · DIN 02237600 · $0.0938
Ratio-Atenolol · DIN 02171791 · $0.0938
Septa-Atenolol · DIN 02368641 · $0.0938
Tenormin · DIN 02039532 · $0.0938
Teva-Atenolol · DIN 01912062 · $0.0938
Shortage status: resolved shortage (ended 2026-02-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02267985
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Ratio-Atenolol · DIN 02171791 · 50mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Ratio-Atenolol · DIN 02171791
Manufacturer: Teva Canada Limited; listing date 1996-10-01
Daily cost (source): $0.0938
Health Canada: Marketed since 2017-11-22 · brand TEVA-ATENOLOL · ATC C07AB03 ATENOLOL · form Tablet · route Oral · ingredients ATENOLOL 50 MG · company Teva canada limited · schedule Prescription
Ratio-Atenolol: Formulary list price $0.0938/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0938 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19691 · Verify on the e-Formulary ↗ (DIN 02171791)
Source record
DIN 02171791: Ratio-Atenolol
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400079; group id 276; item number 0570; lccId None; manufacturer id TEV
Source form: Tab; strength: 50mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0938; ministry $0.0938
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02171791
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19691
Interchangeable products
AG-Atenolol · DIN 02369184 · $0.0938
Apo-Atenol · DIN 00773689 · $0.0938
Atenolol · DIN 02238316 · $0.0938
Atenolol · DIN 02466465 · $0.0938
Jamp-Atenolol · DIN 02367564 · $0.0938
Mar-Atenolol · DIN 02371987 · $0.0938
Mint-Atenol · DIN 02368021 · $0.0938
PMS-Atenolol · DIN 02237600 · $0.0938
Ran-Atenolol · DIN 02267985 · $0.0938
Septa-Atenolol · DIN 02368641 · $0.0938
Tenormin · DIN 02039532 · $0.0938
Teva-Atenolol · DIN 01912062 · $0.0938
Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02171791
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Tenormin · DIN 02039532 · 50mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists Tenormin (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up.
(innovicares.ca ↗)Savings card: RxHelp ONE lists TENORMIN (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim.
(rxhelp.ca ↗)Limit of one Prescription Drug Card Program / Patient Financial Assistance Card from any adjudicator per DIN and claim submitted. The RxHelpONE card CANNOT be combined with any other card or offer. (Terms of Use)
(rxhelp.ca, Sep 10, 2026 ↗)1 brand, same coverage
Tenormin · DIN 02039532
Manufacturer: AstraZeneca; listing date 1996-10-01
Daily cost (source): $0.6150
Health Canada: Marketed since 2022-02-28 · brand TENORMIN · ATC C07AB03 ATENOLOL · form Tablet · route Oral · ingredients ATENOLOL 50 MG · company Searchlight pharma inc · schedule Prescription
Ministry pays: $0.0938 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17905 · Verify on the e-Formulary ↗ (DIN 02039532)
Source record
DIN 02039532: Tenormin
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400079; group id 276; item number 0570; lccId None; manufacturer id AZC
Source form: Tab; strength: 50mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.6150; ministry $0.0938
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02039532
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17905
Interchangeable products
AG-Atenolol · DIN 02369184 · $0.0938
Apo-Atenol · DIN 00773689 · $0.0938
Atenolol · DIN 02238316 · $0.0938
Atenolol · DIN 02466465 · $0.0938
Jamp-Atenolol · DIN 02367564 · $0.0938
Mar-Atenolol · DIN 02371987 · $0.0938
Mint-Atenol · DIN 02368021 · $0.0938
PMS-Atenolol · DIN 02237600 · $0.0938
Ran-Atenolol · DIN 02267985 · $0.0938
Ratio-Atenolol · DIN 02171791 · $0.0938
Septa-Atenolol · DIN 02368641 · $0.0938
Teva-Atenolol · DIN 01912062 · $0.0938
Shortage status: resolved shortage (ended 2024-01-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02039532
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Atenol · DIN 00773697 · 100mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Atenol · DIN 00773697
Manufacturer: Apotex Inc.; listing date 1996-10-01
Daily cost (source): $0.1543
Health Canada: Marketed since 1988-12-31 · brand APO-ATENOL TAB 100MG · ATC C07AB03 ATENOLOL · form Tablet · route Oral · ingredients ATENOLOL 100 MG · company Apotex inc · schedule Prescription
Apo-Atenol: Formulary list price $0.1543/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1543 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9175 · Verify on the e-Formulary ↗ (DIN 00773697)
Source record
DIN 00773697: Apo-Atenol
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400078; group id 276; item number 0571; lccId None; manufacturer id APX
Source form: Tab; strength: 100mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1543; ministry $0.1543
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00773697
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9175
Interchangeable products
AG-Atenolol · DIN 02369192 · $0.1543
Atenolol · DIN 02238318 · $0.1543
Atenolol · DIN 02466473 · $0.1543
Jamp-Atenolol · DIN 02367572 · $0.1543
Mar-Atenolol · DIN 02371995 · $0.1543
Mint-Atenol · DIN 02368048 · $0.1543
PMS-Atenolol · DIN 02237601 · $0.1543
Ran-Atenolol · DIN 02267993 · $0.1543
Ratio-Atenolol · DIN 02171805 · $0.1543
Septa-Atenolol · DIN 02368668 · $0.1543
Tenormin · DIN 02039540 · $0.1543
Teva-Atenolol · DIN 01912054 · $0.1543
Shortage status: active shortage (reported 2025-11-18, last updated 2025-11-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00773697
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Atenolol · DIN 02238318 · 100mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Atenolol · DIN 02238318
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2010-06-14
Daily cost (source): $0.1543
Health Canada: Marketed since 2024-01-05 · brand ATENOLOL · ATC C07AB03 ATENOLOL · form Tablet · route Oral · ingredients ATENOLOL 100 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Atenolol: Formulary list price $0.1543/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1543 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61719 · Verify on the e-Formulary ↗ (DIN 02238318)
Source record
DIN 02238318: Atenolol
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400078; group id 276; item number 0571; lccId None; manufacturer id SIV
Source form: Tab; strength: 100mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1543; ministry $0.1543
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02238318
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61719
Interchangeable products
AG-Atenolol · DIN 02369192 · $0.1543
Apo-Atenol · DIN 00773697 · $0.1543
Atenolol · DIN 02466473 · $0.1543
Jamp-Atenolol · DIN 02367572 · $0.1543
Mar-Atenolol · DIN 02371995 · $0.1543
Mint-Atenol · DIN 02368048 · $0.1543
PMS-Atenolol · DIN 02237601 · $0.1543
Ran-Atenolol · DIN 02267993 · $0.1543
Ratio-Atenolol · DIN 02171805 · $0.1543
Septa-Atenolol · DIN 02368668 · $0.1543
Tenormin · DIN 02039540 · $0.1543
Teva-Atenolol · DIN 01912054 · $0.1543
Shortage status: resolved shortage (ended 2018-07-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02238318
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp-Atenolol · DIN 02367572 · 100mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp-Atenolol · DIN 02367572
Manufacturer: Jamp Pharma Corporation; listing date 2012-01-19
Daily cost (source): $0.1543
Health Canada: Marketed since 2011-06-09 · brand JAMP-ATENOLOL · ATC C07AB03 ATENOLOL · form Tablet · route Oral · ingredients ATENOLOL 100 MG · company Jamp pharma corporation · schedule Prescription
Jamp-Atenolol: Formulary list price $0.1543/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1543 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85241 · Verify on the e-Formulary ↗ (DIN 02367572)
Source record
DIN 02367572: Jamp-Atenolol
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400078; group id 276; item number 0571; lccId None; manufacturer id JPC
Source form: Tab; strength: 100mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1543; ministry $0.1543
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02367572
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85241
Interchangeable products
AG-Atenolol · DIN 02369192 · $0.1543
Apo-Atenol · DIN 00773697 · $0.1543
Atenolol · DIN 02238318 · $0.1543
Atenolol · DIN 02466473 · $0.1543
Mar-Atenolol · DIN 02371995 · $0.1543
Mint-Atenol · DIN 02368048 · $0.1543
PMS-Atenolol · DIN 02237601 · $0.1543
Ran-Atenolol · DIN 02267993 · $0.1543
Ratio-Atenolol · DIN 02171805 · $0.1543
Septa-Atenolol · DIN 02368668 · $0.1543
Tenormin · DIN 02039540 · $0.1543
Teva-Atenolol · DIN 01912054 · $0.1543
Shortage status: resolved shortage (ended 2017-09-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02367572
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mar-Atenolol · DIN 02371995 · 100mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mar-Atenolol · DIN 02371995
Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2012-01-19
Daily cost (source): $0.1543
Health Canada: Marketed since 2012-10-22 · brand MAR-ATENOLOL · ATC C07AB03 ATENOLOL · form Tablet · route Oral · ingredients ATENOLOL 100 MG · company Marcan pharmaceuticals inc · schedule Prescription
Mar-Atenolol: Formulary list price $0.1543/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1543 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85712 · Verify on the e-Formulary ↗ (DIN 02371995)
Source record
DIN 02371995: Mar-Atenolol
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400078; group id 276; item number 0571; lccId None; manufacturer id MAR
Source form: Tab; strength: 100mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1543; ministry $0.1543
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02371995
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85712
Interchangeable products
AG-Atenolol · DIN 02369192 · $0.1543
Apo-Atenol · DIN 00773697 · $0.1543
Atenolol · DIN 02238318 · $0.1543
Atenolol · DIN 02466473 · $0.1543
Jamp-Atenolol · DIN 02367572 · $0.1543
Mint-Atenol · DIN 02368048 · $0.1543
PMS-Atenolol · DIN 02237601 · $0.1543
Ran-Atenolol · DIN 02267993 · $0.1543
Ratio-Atenolol · DIN 02171805 · $0.1543
Septa-Atenolol · DIN 02368668 · $0.1543
Tenormin · DIN 02039540 · $0.1543
Teva-Atenolol · DIN 01912054 · $0.1543
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02371995
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mint-Atenol · DIN 02368048 · 100mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mint-Atenol · DIN 02368048
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2012-01-19
Daily cost (source): $0.1543
Health Canada: Marketed since 2011-06-13 · brand MINT-ATENOL · ATC C07AB03 ATENOLOL · form Tablet · route Oral · ingredients ATENOLOL 100 MG · company Mint pharmaceuticals inc · schedule Prescription
Mint-Atenol: Formulary list price $0.1543/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1543 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85285 · Verify on the e-Formulary ↗ (DIN 02368048)
Source record
DIN 02368048: Mint-Atenol
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400078; group id 276; item number 0571; lccId None; manufacturer id MIN
Source form: Tab; strength: 100mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1543; ministry $0.1543
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02368048
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85285
Interchangeable products
AG-Atenolol · DIN 02369192 · $0.1543
Apo-Atenol · DIN 00773697 · $0.1543
Atenolol · DIN 02238318 · $0.1543
Atenolol · DIN 02466473 · $0.1543
Jamp-Atenolol · DIN 02367572 · $0.1543
Mar-Atenolol · DIN 02371995 · $0.1543
PMS-Atenolol · DIN 02237601 · $0.1543
Ran-Atenolol · DIN 02267993 · $0.1543
Ratio-Atenolol · DIN 02171805 · $0.1543
Septa-Atenolol · DIN 02368668 · $0.1543
Tenormin · DIN 02039540 · $0.1543
Teva-Atenolol · DIN 01912054 · $0.1543
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02368048
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Atenolol · DIN 02237601 · 100mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PMS-Atenolol · DIN 02237601
Manufacturer: Pharmascience Inc.; listing date 1999-04-15
Daily cost (source): $0.1543
Health Canada: Marketed since 1998-03-31 · brand PMS-ATENOLOL · ATC C07AB03 ATENOLOL · form Tablet · route Oral · ingredients ATENOLOL 100 MG · company Pharmascience inc · schedule Prescription
PMS-Atenolol: Formulary list price $0.1543/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1543 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60940 · Verify on the e-Formulary ↗ (DIN 02237601)
Source record
DIN 02237601: PMS-Atenolol
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400078; group id 276; item number 0571; lccId None; manufacturer id PMS
Source form: Tab; strength: 100mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1543; ministry $0.1543
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02237601
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60940
Interchangeable products
AG-Atenolol · DIN 02369192 · $0.1543
Apo-Atenol · DIN 00773697 · $0.1543
Atenolol · DIN 02238318 · $0.1543
Atenolol · DIN 02466473 · $0.1543
Jamp-Atenolol · DIN 02367572 · $0.1543
Mar-Atenolol · DIN 02371995 · $0.1543
Mint-Atenol · DIN 02368048 · $0.1543
Ran-Atenolol · DIN 02267993 · $0.1543
Ratio-Atenolol · DIN 02171805 · $0.1543
Septa-Atenolol · DIN 02368668 · $0.1543
Tenormin · DIN 02039540 · $0.1543
Teva-Atenolol · DIN 01912054 · $0.1543
Shortage status: discontinued (2023-09-08, reported by PHARMASCIENCE INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02237601
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Ran-Atenolol · DIN 02267993 · 100mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Ran-Atenolol · DIN 02267993
Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2006-03-01
Daily cost (source): $0.1543
Health Canada: Marketed since 2020-01-23 · brand TARO-ATENOLOL · ATC C07AB03 ATENOLOL · form Tablet · route Oral · ingredients ATENOLOL 100 MG · company Sun pharma canada inc · schedule Prescription
Ran-Atenolol: Formulary list price $0.1543/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1543 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75338 · Verify on the e-Formulary ↗ (DIN 02267993)
Source record
DIN 02267993: Ran-Atenolol
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400078; group id 276; item number 0571; lccId None; manufacturer id RAN
Source form: Tab; strength: 100mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1543; ministry $0.1543
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02267993
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75338
Interchangeable products
AG-Atenolol · DIN 02369192 · $0.1543
Apo-Atenol · DIN 00773697 · $0.1543
Atenolol · DIN 02238318 · $0.1543
Atenolol · DIN 02466473 · $0.1543
Jamp-Atenolol · DIN 02367572 · $0.1543
Mar-Atenolol · DIN 02371995 · $0.1543
Mint-Atenol · DIN 02368048 · $0.1543
PMS-Atenolol · DIN 02237601 · $0.1543
Ratio-Atenolol · DIN 02171805 · $0.1543
Septa-Atenolol · DIN 02368668 · $0.1543
Tenormin · DIN 02039540 · $0.1543
Teva-Atenolol · DIN 01912054 · $0.1543
Shortage status: resolved shortage (ended 2023-02-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02267993
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Ratio-Atenolol · DIN 02171805 · 100mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Ratio-Atenolol · DIN 02171805
Manufacturer: Teva Canada Limited; listing date 1996-10-01
Daily cost (source): $0.1543
Health Canada: Marketed since 2017-11-22 · brand TEVA-ATENOLOL · ATC C07AB03 ATENOLOL · form Tablet · route Oral · ingredients ATENOLOL 100 MG · company Teva canada limited · schedule Prescription
Ratio-Atenolol: Formulary list price $0.1543/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1543 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19692 · Verify on the e-Formulary ↗ (DIN 02171805)
Source record
DIN 02171805: Ratio-Atenolol
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400078; group id 276; item number 0571; lccId None; manufacturer id TEV
Source form: Tab; strength: 100mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1543; ministry $0.1543
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02171805
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19692
Interchangeable products
AG-Atenolol · DIN 02369192 · $0.1543
Apo-Atenol · DIN 00773697 · $0.1543
Atenolol · DIN 02238318 · $0.1543
Atenolol · DIN 02466473 · $0.1543
Jamp-Atenolol · DIN 02367572 · $0.1543
Mar-Atenolol · DIN 02371995 · $0.1543
Mint-Atenol · DIN 02368048 · $0.1543
PMS-Atenolol · DIN 02237601 · $0.1543
Ran-Atenolol · DIN 02267993 · $0.1543
Septa-Atenolol · DIN 02368668 · $0.1543
Tenormin · DIN 02039540 · $0.1543
Teva-Atenolol · DIN 01912054 · $0.1543
Shortage status: shortage reported ended 2026-05-05 (report last updated 2026-05-05); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02171805
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Tenormin · DIN 02039540 · 100mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists Tenormin (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up.
(innovicares.ca ↗)Savings card: RxHelp ONE lists TENORMIN (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim.
(rxhelp.ca ↗)Limit of one Prescription Drug Card Program / Patient Financial Assistance Card from any adjudicator per DIN and claim submitted. The RxHelpONE card CANNOT be combined with any other card or offer. (Terms of Use)
(rxhelp.ca, Sep 10, 2026 ↗)1 brand, same coverage
Tenormin · DIN 02039540
Manufacturer: AstraZeneca; listing date 1996-10-01
Daily cost (source): $1.0117
Health Canada: Marketed since 2022-02-28 · brand TENORMIN · ATC C07AB03 ATENOLOL · form Tablet · route Oral · ingredients ATENOLOL 100 MG · company Searchlight pharma inc · schedule Prescription
Ministry pays: $0.1543 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17906 · Verify on the e-Formulary ↗ (DIN 02039540)
Source record
DIN 02039540: Tenormin
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400078; group id 276; item number 0571; lccId None; manufacturer id AZC
Source form: Tab; strength: 100mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.0117; ministry $0.1543
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02039540
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17906
Interchangeable products
AG-Atenolol · DIN 02369192 · $0.1543
Apo-Atenol · DIN 00773697 · $0.1543
Atenolol · DIN 02238318 · $0.1543
Atenolol · DIN 02466473 · $0.1543
Jamp-Atenolol · DIN 02367572 · $0.1543
Mar-Atenolol · DIN 02371995 · $0.1543
Mint-Atenol · DIN 02368048 · $0.1543
PMS-Atenolol · DIN 02237601 · $0.1543
Ran-Atenolol · DIN 02267993 · $0.1543
Ratio-Atenolol · DIN 02171805 · $0.1543
Septa-Atenolol · DIN 02368668 · $0.1543
Teva-Atenolol · DIN 01912054 · $0.1543
Shortage status: resolved shortage (ended 2024-01-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02039540
Shortage record checked 2026-09-13T08:10:21.292534+00:00
AG-Atenolol · DIN 02369184 · 50mg · tablet
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
AG-Atenolol · DIN 02369184
Manufacturer: Angita Pharma Inc.; listing date 2020-12-18
Daily cost (source): $0.0938
Health Canada: Dormant since 2025-07-30 · brand AG-ATENOLOL · ATC C07AB03 ATENOLOL · form Tablet · route Oral · ingredients ATENOLOL 50 MG · company Angita pharma inc. · schedule Prescription
AG-Atenolol: Formulary list price $0.0938/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0938 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85412 · Verify on the e-Formulary ↗ (DIN 02369184)
Source record
DIN 02369184: AG-Atenolol
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400079; group id 276; item number 0570; lccId None; manufacturer id ANG
Source form: Tab; strength: 50mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0938; ministry $0.0938
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02369184
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85412
Interchangeable products
Apo-Atenol · DIN 00773689 · $0.0938
Atenolol · DIN 02238316 · $0.0938
Atenolol · DIN 02466465 · $0.0938
Jamp-Atenolol · DIN 02367564 · $0.0938
Mar-Atenolol · DIN 02371987 · $0.0938
Mint-Atenol · DIN 02368021 · $0.0938
PMS-Atenolol · DIN 02237600 · $0.0938
Ran-Atenolol · DIN 02267985 · $0.0938
Ratio-Atenolol · DIN 02171791 · $0.0938
Septa-Atenolol · DIN 02368641 · $0.0938
Tenormin · DIN 02039532 · $0.0938
Teva-Atenolol · DIN 01912062 · $0.0938
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02369184
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2025-07-30 — choose a marketed DIN from the same-category list.
Septa-Atenolol · DIN 02368641 · 50mg · tablet
General benefitDormant since 2017-07-21 · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Septa-Atenolol · DIN 02368641
Manufacturer: Septa Pharmaceuticals Inc.; listing date 2012-03-26
Daily cost (source): $0.0938
Health Canada: Dormant since 2017-07-21 · brand SEPTA-ATENOLOL · ATC C07AB03 ATENOLOL · form Tablet · route Oral · ingredients ATENOLOL 50 MG · company Septa pharmaceuticals inc · schedule Prescription
Septa-Atenolol: Formulary list price $0.0938/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0938 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85364 · Verify on the e-Formulary ↗ (DIN 02368641)
Source record
DIN 02368641: Septa-Atenolol
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400079; group id 276; item number 0570; lccId None; manufacturer id SET
Source form: Tab; strength: 50mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0938; ministry $0.0938
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02368641
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85364
Interchangeable products
AG-Atenolol · DIN 02369184 · $0.0938
Apo-Atenol · DIN 00773689 · $0.0938
Atenolol · DIN 02238316 · $0.0938
Atenolol · DIN 02466465 · $0.0938
Jamp-Atenolol · DIN 02367564 · $0.0938
Mar-Atenolol · DIN 02371987 · $0.0938
Mint-Atenol · DIN 02368021 · $0.0938
PMS-Atenolol · DIN 02237600 · $0.0938
Ran-Atenolol · DIN 02267985 · $0.0938
Ratio-Atenolol · DIN 02171791 · $0.0938
Tenormin · DIN 02039532 · $0.0938
Teva-Atenolol · DIN 01912062 · $0.0938
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02368641
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2017-07-21 — choose a marketed DIN from the same-category list.
AG-Atenolol · DIN 02369192 · 100mg · tablet
General benefitDormant since 2026-08-03 · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
AG-Atenolol · DIN 02369192
Manufacturer: Angita Pharma Inc.; listing date 2020-12-18
Daily cost (source): $0.1543
Health Canada: Dormant since 2026-08-03 · brand AG-ATENOLOL · ATC C07AB03 ATENOLOL · form Tablet · route Oral · ingredients ATENOLOL 100 MG · company Angita pharma inc. · schedule Prescription
AG-Atenolol: Formulary list price $0.1543/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1543 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85413 · Verify on the e-Formulary ↗ (DIN 02369192)
Source record
DIN 02369192: AG-Atenolol
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400078; group id 276; item number 0571; lccId None; manufacturer id ANG
Source form: Tab; strength: 100mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1543; ministry $0.1543
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02369192
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85413
Interchangeable products
Apo-Atenol · DIN 00773697 · $0.1543
Atenolol · DIN 02238318 · $0.1543
Atenolol · DIN 02466473 · $0.1543
Jamp-Atenolol · DIN 02367572 · $0.1543
Mar-Atenolol · DIN 02371995 · $0.1543
Mint-Atenol · DIN 02368048 · $0.1543
PMS-Atenolol · DIN 02237601 · $0.1543
Ran-Atenolol · DIN 02267993 · $0.1543
Ratio-Atenolol · DIN 02171805 · $0.1543
Septa-Atenolol · DIN 02368668 · $0.1543
Tenormin · DIN 02039540 · $0.1543
Teva-Atenolol · DIN 01912054 · $0.1543
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02369192
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2026-08-03 — choose a marketed DIN from the same-category list.
Septa-Atenolol · DIN 02368668 · 100mg · tablet
General benefitDormant since 2017-07-21 · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Septa-Atenolol · DIN 02368668
Manufacturer: Septa Pharmaceuticals Inc.; listing date 2012-03-26
Daily cost (source): $0.1543
Health Canada: Dormant since 2017-07-21 · brand SEPTA-ATENOLOL · ATC C07AB03 ATENOLOL · form Tablet · route Oral · ingredients ATENOLOL 100 MG · company Septa pharmaceuticals inc · schedule Prescription
Septa-Atenolol: Formulary list price $0.1543/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1543 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85365 · Verify on the e-Formulary ↗ (DIN 02368668)
Source record
DIN 02368668: Septa-Atenolol
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400078; group id 276; item number 0571; lccId None; manufacturer id SET
Source form: Tab; strength: 100mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1543; ministry $0.1543
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02368668
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85365
Interchangeable products
AG-Atenolol · DIN 02369192 · $0.1543
Apo-Atenol · DIN 00773697 · $0.1543
Atenolol · DIN 02238318 · $0.1543
Atenolol · DIN 02466473 · $0.1543
Jamp-Atenolol · DIN 02367572 · $0.1543
Mar-Atenolol · DIN 02371995 · $0.1543
Mint-Atenol · DIN 02368048 · $0.1543
PMS-Atenolol · DIN 02237601 · $0.1543
Ran-Atenolol · DIN 02267993 · $0.1543
Ratio-Atenolol · DIN 02171805 · $0.1543
Tenormin · DIN 02039540 · $0.1543
Teva-Atenolol · DIN 01912054 · $0.1543
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02368668
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2017-07-21 — choose a marketed DIN from the same-category list.
Atenolol · DIN 02466465 · 50mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2026-04-27 — choose a marketed DIN from the same-category list.Discontinued 2026-04-27 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2026-04-27 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2026-04-27 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Atenolol · DIN 02466465
Manufacturer: Sanis Health Inc.; listing date 2018-04-01
Daily cost (source): $0.0938
Health Canada: Cancelled post market since 2026-04-27 · brand ATENOLOL · ATC C07AB03 ATENOLOL · form Tablet · route Oral · ingredients ATENOLOL 50 MG · company Sanis health inc · schedule Prescription
Atenolol: Formulary list price $0.0938/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0938 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95482 · Verify on the e-Formulary ↗ (DIN 02466465)
Source record
DIN 02466465: Atenolol
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400079; group id 276; item number 0570; lccId None; manufacturer id SAI
Source form: Tab; strength: 50mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0938; ministry $0.0938
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02466465
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95482
Interchangeable products
AG-Atenolol · DIN 02369184 · $0.0938
Apo-Atenol · DIN 00773689 · $0.0938
Atenolol · DIN 02238316 · $0.0938
Jamp-Atenolol · DIN 02367564 · $0.0938
Mar-Atenolol · DIN 02371987 · $0.0938
Mint-Atenol · DIN 02368021 · $0.0938
PMS-Atenolol · DIN 02237600 · $0.0938
Ran-Atenolol · DIN 02267985 · $0.0938
Ratio-Atenolol · DIN 02171791 · $0.0938
Septa-Atenolol · DIN 02368641 · $0.0938
Tenormin · DIN 02039532 · $0.0938
Teva-Atenolol · DIN 01912062 · $0.0938
Shortage status: anticipated shortage (last updated 2026-04-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02466465
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2026-04-27 — choose a marketed DIN from the same-category list.
Teva-Atenolol · DIN 01912062 · 50mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2015-07-24 — choose a marketed DIN from the same-category list.Discontinued 2015-07-24 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2015-07-24 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2015-07-24 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Atenolol · DIN 01912062
Manufacturer: Teva Canada Limited; listing date 1996-10-01
Daily cost (source): $0.0938
Health Canada: Cancelled post market since 2015-07-24 · brand TEVA-ATENOLOL · ATC C07AB03 ATENOLOL · form Tablet · route Oral · ingredients ATENOLOL 50 MG · company Teva canada limited · schedule Prescription
Teva-Atenolol: Formulary list price $0.0938/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0938 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11143 · Verify on the e-Formulary ↗ (DIN 01912062)
Source record
DIN 01912062: Teva-Atenolol
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400079; group id 276; item number 0570; lccId None; manufacturer id TEV
Source form: Tab; strength: 50mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0938; ministry $0.0938
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01912062
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11143
Interchangeable products
AG-Atenolol · DIN 02369184 · $0.0938
Apo-Atenol · DIN 00773689 · $0.0938
Atenolol · DIN 02238316 · $0.0938
Atenolol · DIN 02466465 · $0.0938
Jamp-Atenolol · DIN 02367564 · $0.0938
Mar-Atenolol · DIN 02371987 · $0.0938
Mint-Atenol · DIN 02368021 · $0.0938
PMS-Atenolol · DIN 02237600 · $0.0938
Ran-Atenolol · DIN 02267985 · $0.0938
Ratio-Atenolol · DIN 02171791 · $0.0938
Septa-Atenolol · DIN 02368641 · $0.0938
Tenormin · DIN 02039532 · $0.0938
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=01912062
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2015-07-24 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary classes and how they are covered
Other drugs in the same formulary class (24:04 Cardiac Drugs) and how they are covered
Matched class: 24:04 Cardiac Drugs
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: DIGOXIN, PROPAFENONE HCL
Some products covered without a code (check the product listing): ACEBUTOLOL HCL, AMIODARONE HCL, AMLODIPINE, BISOPROLOL FUMARATE, DILTIAZEM HCL, DISOPYRAMIDE, FLECAINIDE ACETATE, METOPROLOL TARTRATE, MEXILETINE HCL, NADOLOL, NIFEDIPINE, PROPRANOLOL, SOTALOL HCL, TIMOLOL MALEATE, VERAPAMIL HCL
24:00 CARDIOVASCULAR DRUGS
· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 500mg · ER Tab
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:00
24:04 Cardiac Drugs
· 9 products · Listed, not a benefit (3), General benefit (6) · strengths: 100mg, 200mg, 400mg · Tab
· 20 products · General benefit (18), Listed, not a benefit (2) · strengths: 1.25mg, 2.5mg, 5mg, 10mg · Tab
· 28 products · Listed, not a benefit (6), General benefit (22) · strengths: 100mg, 200mg, 50mg · LA Tab, Tab
· 8 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2.5mg, 5mg, 10mg, 20mg · Tab
· 8 products · Listed, not a benefit (3), General benefit (5) · strengths: 40mg, 80mg, 160mg · Tab
· 19 products · Off-Formulary Interchangeable, not an ODB benefit (8), General benefit (7), Listed, not a benefit (4) · strengths: 60mg, 80mg, 120mg, 160mg, 10mg, 20mg, 40mg · LA Cap, Tab
· 10 products · Listed, not a benefit (2), General benefit (8) · strengths: 80mg, 160mg · Tab
· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 20mg · Tab
· 36 products · Listed, not a benefit (4),
Limited Use, codes 183 (32) · strengths: 3.125mg, 6.25mg, 12.5mg, 25mg · Tab
· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 200mg · Tab
· 56 products ·
Limited Use, codes 645, 706 (1), Off-Formulary Interchangeable, not an ODB benefit (11), General benefit (44) · strengths: 1mg/mL, 2.5mg, 5mg, 10mg · Oral Sol, Tab
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:04
and 9 more
Other drugs in the same formulary class (24:08 Hypotensive Drugs (For Diuretics See 40:28)) and how they are covered
Matched class: 24:08 Hypotensive Drugs (For Diuretics See 40:28)
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE, LABETALOL HCL, LOSARTAN POTASSIUM, LOSARTAN POTASSIUM & HYDROCHLOROTHIAZIDE, MINOXIDIL, OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL & HYDROCHLOROTHIAZIDE, PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE & INDAPAMIDE, PINDOLOL & HYDROCHLOROTHIAZIDE, TELMISARTAN, TELMISARTAN & AMLODIPINE BESYLATE, TELMISARTAN & HYDROCHLOROTHIAZIDE, VALSARTAN & HYDROCHLOROTHIAZIDE
Some products covered without a code (check the product listing): BENAZEPRIL, CAPTOPRIL, CILAZAPRIL, CLONIDINE HCL, DOXAZOSIN MESYLATE, ENALAPRIL MALEATE, FELODIPINE, FOSINOPRIL SODIUM, HYDRALAZINE HCL, IRBESARTAN, IRBESARTAN & HYDROCHLOROTHIAZIDE, LISINOPRIL, LISINOPRIL & HYDROCHLOROTHIAZIDE, METHYLDOPA, NIFEDIPINE, PINDOLOL, PRAZOSIN HCL, QUINAPRIL, QUINAPRIL & HYDROCHLOROTHIAZIDE, RAMIPRIL, RAMIPRIL & HYDROCHLOROTHIAZIDE, TERAZOSIN HCL, TRANDOLAPRIL, VALSARTAN, VERAPAMIL HCL
24:08 Hypotensive Drugs (For Diuretics See 40:28)
· 6 products · General benefit · strengths: 100mg, 200mg · Tab
· 6 products · General benefit (5), Listed, not a benefit (1) · strengths: 5mg, 10mg, 15mg · Tab
· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 20mg · Tab
· 59 products · General benefit · strengths: 4mg, 8mg, 16mg, 32mg · Tab
· 21 products · General benefit · strengths: 16mg & 12.5mg, 32mg & 12.5mg, 32mg & 25mg · Tab
· 14 products ·
Limited Use, codes 707, 723 (2), Listed, not a benefit (4), General benefit (8) · strengths: 5mg/5mL, 25mg/5mL, 12.5mg, 25mg, 50mg, 100mg · Oral Sol, Tab
· 8 products · Listed, not a benefit (2), General benefit (6) · strengths: 1mg, 2.5mg, 5mg · Tab
· 2 products · General benefit · strengths: 5mg/12.5mg · Tab
· 17 products · Off-Formulary Interchangeable, not an ODB benefit (7), Listed, not a benefit (2), General benefit (8) · strengths: 0.025mg, 0.1mg, 0.2mg · Tab
· 12 products · Listed, not a benefit (3), General benefit (9) · strengths: 1mg, 2mg, 4mg · Tab
· 52 products · Listed, not a benefit (1), General benefit (51) · strengths: 2.5mg, 5mg, 10mg, 20mg · Tab
· 12 products · General benefit (10), Listed, not a benefit (2) · strengths: 2.5mg, 5mg, 10mg · ER Tab, SR Tab
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:08
and 35 more